JG
ACRS icon

Jefferies Group’s Aclaris Therapeutics ACRS Stock Holding History

Jefferies Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,063
Closed -$704K – 1681
2021
Q2 		$704K Buy
+40,063
New +$910K ﹤0.01% 1083
2019
Q2 		– Sell
-21,235
Closed -$127K – 2468
2019
Q1 		$127K Sell
21,235
-9,602
-31% -$63.6K ﹤0.01% 2063
2018
Q4 		$228K Buy
30,837
+14,070
+84% +$145K ﹤0.01% 1769
2018
Q3 		$243K Buy
+16,767
New +$287K ﹤0.01% 1990
2017
Q2 		– Sell
-63,908
Closed -$1.91M – 2129
2017
Q1 		$1.91M Buy
+63,908
New +$1.84M 0.01% 942

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Jefferies Group's ACRS Position: Q3 2021 in Review

Jefferies Group sold out of Aclaris Therapeutics (ACRS) in Q3 2021, closing a stake of 40,063 shares — an estimated $704K sold.

Jefferies Group first reported a position in ACRS in Q1 2017 and held it in 5 quarters. The position peaked at $1.91M in Q1 2017. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

  • Jefferies Group reported no remaining Aclaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Jefferies Group sold 40,063 Aclaris Therapeutics shares in Q3 2021, an estimated $704K.
  • Jefferies Group first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 5 quarters.
  • Jefferies Group's Aclaris Therapeutics position peaked at $1.91M in Q1 2017.
  • 126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.